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Background: The orphan receptors COUP-TF (chicken ovalbumin upstream promoter transcription factor) I and II
are members of the nuclear receptor superfamily that play distinct and critical roles in vertebrate organogenesis.
The involvement of COUP-TFs in cancer development has recently been suggested by several studies but remains
poorly understood.
Methods: MCF-7 breast cancer cells overexpressing COUP-TFI and human breast tumors were used to investigate
the role of COUP-TFI in the regulation of CXCL12/CXCR4 signaling axis in relation to cell growth and migration. We
used Immunofluorescence, western-blot, RT-PCR, Formaldehyde-assisted Isolation of Regulatory Elements (FAIRE)
assays, as well as cell proliferation and migration assays.
Results: Previously, we showed that COUP-TFI expression is enhanced in breast cancer compared to normal tissue.
Here, we report that the CXCL12/CXCR4 signaling pathway, a crucial pathway in cell growth and migration, is an
endogenous target of COUP-TFI in breast cancer cells. The overexpression of COUP-TFI in MCF-7 cells inhibits the
expression of the chemokine CXCL12 and markedly enhances the expression of its receptor, CXCR4. Our results
demonstrate that the modification of CXCL12/CXCR4 expression by COUP-TFI is mediated by the activation of
epithelial growth factor (EGF) and the EGF receptor. Furthermore, we provide evidence that these effects of
COUP-TFI increase the growth and motility of MCF-7 cells in response to CXCL12. Cell migration toward a CXCL12
gradient was inhibited by AMD3100, a specific antagonist of CXCR4, or in the presence of excess CXCL12 in the cell
culture medium. The expression profiles of CXCR4, CXCR7, CXCL12, and COUP-TFI mRNA in 82 breast tumors and
control non-tumor samples were measured using real-time PCR. CXCR4 expression was found to be significantly
increased in the tumors and correlated with the tumor grade, whereas the expression of CXCL12 was significantly
decreased in the tumors compared with the healthy samples. Significantly higher COUP-TFI mRNA expression was
also detected in grade 1 tumors.
Conclusions: Together, our mechanistic in vitro assays and in vivo results suggest that a reduction in chemokine
CXCL12 expression, with an enhancement of CXCR4 expression, provoked by COUP-TFI, could be associated with
an increase in the invasive potential of breast cancer cells.
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During cancer progression, cancer cells first proliferate
in the primary cancer site before the acquisition of the
migratory behavior that leads to their spread in the body
and ultimately to the development of metastasis. Estradiol
(E2) and estrogen receptor alpha (ERα) play pivotal roles
during ERα-positive breast cancer progression: E2-ERα
signaling contributes to cell growth but prevents meta-
static potential by preserving the differentiated status of
the cells [1-4]. Although the loss of estrogenic signaling is
generally associated with disease aggravation, the process
remains poorly understood [4-7]. Indeed, many mecha-
nisms may be involved because growth factors assume the
control of cell growth and migratory capacities [1,4]. We
have previously identified COUP-TFI (chicken ovalbumin
upstream promoter transcription factor I) as a promoter
of estrogen-independent ERα transcriptional activity in
breast cancer cell lines [8,9]. Moreover, COUP-TFI
was found to be overexpressed in breast tumors and
to enhance the proliferation of ER-positive breast can-
cer cells [9]. COUP-TFI and COUP-TFII are orphan nu-
clear receptors that can also act by modulating other
nuclear receptors, including ERα, functioning selectively
as a co-activator or a co-repressor [10] to control bio-
logical processes linked to cellular growth, migration, or
angiogenesis and potentially contributing to cancer pro-
gression [10-12]. Particularly, COUP-TFI expression is
associated with the migration behavior of various cells
during embryonic development. Accordingly, evidence
from several studies supports that COUP-TFI and COUP-
TFII expression in cancer cells may be associated with a
dedifferentiation phenotype, the reactivation of embryonic
pathways, and migration behavior, supporting the induc-
tion of aggressive characteristics in cancers [11-14]. Al-
though COUP-TFI is suggested to be a potent mediator
of cancer progression, little is known about the en-
dogenous targets of this orphan nuclear receptor in breast
cancer cells.
The chemokine CXCL12 signaling axis may represent
one such axis. This signaling pathway, which is com-
posed of the chemokine CXCL12 (also called SDF-1 for
stromal cell-derived factor 1) and its receptors CXCR4
and CXCR7, play pivotal roles in the cell migration,
angiogenesis, proliferation, and survival of many cancer
cells, including breast cancer [15,16]. CXCR4 is typically
highly expressed in metastatic cells and supports the pri-
vileged homing of these metastatic cells to specific sites
where the local secretion of CXCL12 is important, namely
the bone, liver, brain, and lung [17-19]. Indeed, reduction
or the loss of the local secretion of CXCL12 at the tumor
site can induce the emergence of metastatic cells that
may spread in the organism toward endocrine sources
of CXCL12 [20-22]. Although the pivotal role of the
CXCL12/CXCR4 axis in cell motility and consequently incancer metastasis in several tissues is well established,
the contribution of CXCL12 via its receptor CXCR7 is
less understood.
CXCL12 signaling may be connected to the pheno-
typic characteristics modified by COUP-TFI; thus, we
hypothesized that COUP-TFI could target this signaling
pathway in breast cancer cells. Furthermore, as the en-
tire CXCL12/CXCR4 signaling axis is an endogenous
target of E2 and is pivotal to hormonal-induced MCF-7
cell growth [23], COUP-TFI could achieve the loss of its
estrogenic regulation. In the present study, we developed
MCF-7 breast cancer cells overexpressing COUP-TFI
protein and examined the regulation of CXCL12 signal-
ing axis. We provide evidence that COUP-TFI increases
the motility of MCF-7 ERα-positive breast cancer cells
by acting on CXCL12/CXCR4 signaling as an endogen-
ous target. The modification of CXCL12/CXCR4 expres-
sion by COUP-TFI is mediated by the activation of
epithelial growth factor (EGF) and its receptor (EGFR)
in MCF-7 cells. These results correlate with the expres-
sion profiles of COUP-TFI, CXCL12, and CXCR4 in
breast tumors compared to healthy samples.
Methods
Antibodies and reagents
A goat polyclonal antibody against human CXCL12 (R&D
Systems AF-310-NA), rabbit polyclonal antibody against
CXCR4 (Abcam Inc. ab2074), mouse monoclonal anti-
body against human CXCR7/RDC1 (R&D Systems clone
11G8; MAB42273), a rabbit polyclonal antibody against
COUP-TFI (Abcam Inc. ab11954) and a rabbit poly-
clonal antibody against HA epitope (Santa Cruz sc-805)
were used for the immunofluorescence and western blot
assays. A mouse polyclonal antibody against phosphory-
lated ERK (Santa Cruz sc-7983) and rabbit polyclonal anti-
body against total ERK (Santa Cruz sc-94) were used for
the western blot assays.
The reagents used for treatments (17-β-estradiol (E2),
ICI182,780 (ICI), and AMD3100) were purchased from
Sigma-Aldrich Co. The recombinant CXCL12 used for
the proliferation and migration assays was purchased from
R&D Systems (350-NS-050).
Cell culture and treatments
MCF-7 cells were routinely maintained in DMEM (Invi-
trogen) supplemented with 10% fetal bovine serum (FBS;
Biowest) and antibiotics (Invitrogen) at 37°C in 5% CO2.
Stably transfected MCF-7 clones were obtained as previ-
ously described [9]. A pool of two independent control
clones and two independent COUP-TFI-overexpressing
(COUP) clones were used for this study.
When treatments with steroids were required, the cells
were maintained for 24 h in DMEM without phenol red
(Invitrogen) supplemented with 2.5% dextran-treated
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The treatments were then performed in phenol red-free
DMEM with 2.5% dsFBS and E2 (10−8 M), ICI (10−6 M),
or both together for 48 hours; 0.1% ethanol was used as
a control (EtOH).
Immunofluorescence
Cells were plated on 10 mm‐diameter cover slides in 24‐
well plates (5 × 104 cells per well). After 48 h, the cells
were fixed for 10 min in phosphate‐buffered saline (PBS)
containing 4% paraformaldehyde. The cells were then
permeabilized in PBS containing 0.3% Triton X‐100 for
10 min. The primary antibodies were diluted (1:100) in PBS
containing 3% FCS and added to the permeabilized cells,
which were incubated over night at 4°C. Dye-conjugated
secondary antibodies (1:1000, Alexa Fluor, Invitrogen)
were incubated 1 h at room temperature. After mounting
in Vectashield® mounting medium with DAPI (Vector),
images were obtained using an Imager.Z1 ApoTome
AxioCam (Zeiss) epifluorescence microscope and proc-
essed with Axio Vision Software.
RT-PCR assays
2.5 × 105 cells were cultured in 6-well plates and treated
as specified. Total RNA was extracted, at least in tripli-
cate, using the Trizol™ reagent (Invitrogen) according to
the manufacturer’s instructions. cDNA was generated by
MMLV Reverse transcriptase (Invitrogen) using random
hexamers (Promega). Quantitative real-time RT-PCR was
performed using the iQ SybrGreen supermix (Bio-Rad,
Hercules) and a Bio-Rad MyiQ apparatus. The primers
(Proligo Primers and Probes, Boulder, CO, USA) used for
the cDNA amplifications in the quantitative RT-PCR ex-
periments are described in Table 1. GAPDH and RNA 18S
were used as housekeeping genes to normalize the expres-
sion levels of the genes of interest. GAPDH was found to
be appropriate for normalisation in cell lines because its
expression was not affected by treatments and remained
stable in control and COUP clones. For tissues, we first
verified the choice of the reference gene as an internal con-
trol and its suitability in our study. Four housekeepingTable 1 Sequences of primers used in this study
Gene name and symbol F
Chemokine (C-X-C motif) receptor 4 (CXCR4) G
Chemokine (C-X-C motif) receptor 7 (CXCR7) A
Chemokine (C-X-C motif) ligand 12 (CXCL12) C
Nuclear receptor subfamily 2, group F, member 1 (NR2F1) (COUP-TFI) T
Epidermal Growth Factor (EGF) C
Epidermal Growth Factor receptor (EGFR) G
GlycerAldehyde-3-Phosphate DesHydrogenase (GAPDH) G
18S RNA Ggenes were tested (GAPDH, HPRT1, TBP and 18S RNA).
The stability of these genes across different tissues and
tumor grades was assessed using geNorm algorithm [24].
This software has listed HPRT1 as the best gene but
HPRT1 is expressed at very low level in normal tissues and
tumors, making it quite difficult to accurately quantify and
not enough useful as an internal reference in our study.
The second best gene, established by the software in the
list, was the 18S RNA. This RNA is expressed similarly
at relatively high levels in all tumors and made ideal posi-
tive control for our study. Thus, we have chosen 18S for
normalization.
Melting curves and PCR efficiency analyses were per-
formed to confirm correct amplification. Each experi-
ment was performed at least three times. Results were
expressed according to the comparative Ct method
(ddCt) for relative quantification of gene expression. For
each sample, the difference (dCt) was calculated between
Ct values obtained for target and reference amplicons.
Comparative ddCt was then determined using as a refer-
ence the dCT calculated for the vehicle control sample
(ethanol), and absolute values for comparative expres-
sion level were determined as equal to 2-ddCt.
Protein extraction/Western blotting
Total proteins were extracted in RIPA buffer (1% NP40,
0.5% Na-deoxycholate, and 1% SDS in PBS) with an
anti-protease mixture (Complete EDTA free Antiproteases,
Roche) and quantified using the Bio Rad DC protein assay
kit. The proteins were diluted in Laemmli buffer and dena-
tured at 95°C; 30 μg of denatured proteins were separated
on SDS polyacrylamide gels (10 and 15%), transferred to
polyvinylidene difluoride membranes (Millipore), and
probed with specific antibodies. The antibodies used
for the Western blot assays were diluted 1:2000 (for the
detection of COUP-TFI, HA, CXCL12, CXCR4 and
CXCR7) or 1:5000 (for the detection of ERK or P-ERK).
The detection of the immunocomplexes was performed
using an enhanced chemiluminescence system (Immune
Star, Bio-Rad Laboratories). For the detection of ERK ac-
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for 5 or 10 min) or CXCL12 (200 ng/mL for 5 or 10 min)
stimulation, whole-cell extracts were directly prepared in
3× Laemmli buffer. Following sonication, the protein ex-
tracts were denatured for 5 min at 95°C and analyzed as
detailed above.
Formaldehyde-assisted Isolation of Regulatory Elements
(FAIRE)
FAIRE was performed as described by Eeckhoute et al.
[25]. Briefly, asynchronously growing MCF-7 cells (60-
70% confluence) treated or not for 48 h with 10−8 M E2
were cross-linked with 1% formaldehyde for 10 min at
room temperature. Glycine was added to a final concen-
tration of 125 mM, and the cells were rinsed with cold
PBS and harvested. The cells were lysed with a solution
of 1% SDS, 10 mM EDTA, and 50 mM Tris-HCl
(pH 8.1) containing a protease inhibitor cocktail (Roche)
and then sonicated for 14 min (30-sec on/off cycles)
using a Bioruptor (Diagenode) set at the highest inten-
sity. The soluble chromatin was subjected to three con-
secutive phenol-chloroform extractions (Sigma, P3803)
and incubated overnight at 65°C to reverse the cross-
linking. The DNA was then purified using the MinElute
PCR purification kit (Qiagen). The relative enrichment
of open chromatin for the CXCL12, CXCR4 and CXCR7
genes was quantified by real-time PCR performed using
the iQ SybrGreen supermix and a Bio-Rad MyiQ appar-
atus. The primers used for the quantitative PCR experi-
ments were described previously [23].
Proliferation assay
A total of 2500 MCF-7 cells clones per well were seeded
in 96-well plates and cultured in 100 μL of phenol red-free
DMEM/2.5% dsFBS and EtOH or CXCL12 (200 ng/mL)
for 7 days. Every 2 days, the medium was removed,
and fresh treatments were performed. Proliferation was
evaluated using the 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT; Sigma) assay. 10-μL
of 5 mg/mL MTT solution was added to 100 μL of cul-
ture medium in each well and incubated for 2 h at
37°C. The supernatant was removed, and the formazan
formed was dissolved in 100 μL DMSO. The absorbance
of each well at 570 nm was measured using a microplate
reader (Bio-Rad).
Migration assay
The cells were cultured for 48 h in phenol red-free
DMEM with 5% dsFBS prior to the experiments. A total
of 50,000 cells were plated in the upper chamber of a
BDBiocoat control insert (BD Biosciences) in phenol
red-free DMEM/0.5% dsFBS with or without AMD3100
(50 μM) or CXCL12 (200 ng/mL); phenol red-free DMEM/
2.5% dsFBS with or without AMD3100 (50 μM) or CXCL12(200 ng/mL) was added to the lower chamber. The cells
were allowed to migrate for 24 h at 37°C, and the non-
migrant cells were wiped off the upper chamber with a
cotton swab. The insert was then placed in phenol red-
free DMEM/2.5% dsFBS with calcein-AM (Invitrogen) for
1 h to stain the cells that reached the lower side of the fil-
ter. The migrant cells were then counted in 3 fields from
at least 3 inserts per experimental condition.
Ethics statement
Human samples were obtained from the processing of
biological samples through the Centre de Ressources
Biologiques (CRB)-Santé of Rennes (http://www.crbsante-
rennes.com). We have received written informed consent
from all patients for the use of their samples analyzed in
this study. The research protocol was conducted under
French legal guidelines and approved by the local insti-
tutional ethics committee (CPP, Comité de Protection
des Personnes Ouest V de Rennes) in accordance with
Helsinki Declaration. The collection of samples is re-
ported to the Ministry of Education and Research No.
DC-2008-338 which is consistent with the current ethics
legislation.
Gene expression in breast tumors
The breast tumor samples used were invasive ductal car-
cinoma and mostly (> 90%) ER-positive. They were di-
vided into 20 SBR (Scarff-Bloom-Richardson grading
system) Grade 1, 20 SBR Grade 2, 19 SBR Grade 3, and
23 non-tumor tissues. All samples used in this study
were from fresh frozen tissues. The normal breast tissues
were adjacent to the tumors but they are majority un-
matched to the tumors. Total RNA was extracted using
the RNeasy Mini kit (Qiagen) according to the manufac-
turer’s instructions, and 1 μg of total RNA was reverse
transcribed with M-MLV RT (Invitrogen). Gene expres-
sion was assessed by real-time PCR (MyiQ5–Bio-Rad)
with 4 ng of cDNA, 150 mM of primers (shown in
Table 1), and 1× of iQ™ SYBR® Green supermix from
Bio-Rad (Bio-Rad, Hercules, CA, USA). Gene expression
was also measured in MCF-7 cells and served to adjust
the data from different plates. The data were normalized
to the expression of 18S RNA and were analyzed using
IQ5 software (Bio-Rad).
Statistical analysis
A statistical analysis was performed using Student’s
t-test for most of the presented results. The values are
provided as the mean ± standard error of the mean (SEM)
and were considered statistically significant at p < 0.05.
The statistical analysis for the tumor samples was per-
formed using Minitab 16 software. The data are repre-
sented by box plots. The absence of a normal distribution
of each gene for each category was verified by the
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Mann-Whitney test was chosen to analyze our samples.
Results
COUP-TFI overexpression modifies the basal expression of
CXCL12 and CXCR4 but not CXCR7
Our results and those of others have identified the
CXCL12/CXCR4/CXCR7 axis as an important regulator
of the proliferation/migration balance [17-23,26], two
mechanisms that can be modulated by COUP-TFI [9,11].
For this reason, we decided to investigate the impact of
COUP-TFI expression on the CXCL12 signaling axis in
breast cancer cells.
MCF-7 cells were used as an ERα-positive breast cancer
cell model: these cells weakly express COUP-TFI [9,27]
and represent a good model for the study of the function
of COUP-TFI upon overexpression. To investigate the
influence of COUP-TFI on the regulation of CXCL12,
CXCR4, and CXCR7 gene expression, we generated MCF-
7 cell clones that stably express the full-length COUP-TFIFigure 1 COUP-TFI modifies the expression of the CXCL12 signaling a
clones. An immunofluorescence cytochemistry assay was used to detect th
control (Cont.) and COUP clones. The cells were fixed and processed for im
stained with DAPI. (B) CXCL12, CXCR4, and CXCR7 mRNAs were quantifi
control and COUP clones. The results were normalized to GAPDH mRNA u
mRNA expression level of CXCL12, CXCR4, or CXCR7. Data are the mean values
significant differences (p < 0.05) between the control and COUP clones. (C) Th
and CXCR7 protein was determined from whole-cell extracts of the different
blot is shown. (D) The control and COUP clones were fixed, and an im
expression of CXCL12, CXCR4, and CXCR7 proteins. Staining with DAPI is alsotagged with an HA epitope (named COUP); control cells
were obtained from transfection with the empty vector
(control). The expression of COUP-TFI was first verified
in the control and COUP MCF-7 cell clones. Immuno-
fluorescence using an antibody against the HA epitope
confirmed the absence of staining in the control cells,
whereas the COUP cells showed intense staining, mainly
in the nucleus, corresponding to the nuclear receptor
HA-COUP-TFI (Figure 1A). We also confirmed these
results using an anti-COUP-TFI antibody. As shown in
Figure 1, the control cells express a low level of endogen-
ous COUP-TFI, though COUP-TFI staining is higher in
the COUP cells (Figure 1A). These results were also veri-
fied by western blotting (Figure 1C). Then, the levels of
CXCL12, CXCR4, and CXCR7 transcripts in the control
clones and COUP clones were monitored using real-time
quantitative RT-PCR. Two independent control clones
and two independent COUP clones were used, and the re-
sults shown in Figure 1B represent the mean of the data.
Interestingly, the overexpression of the COUP-TFI proteinxis in MCF-7 cells. (A) Characterization of the control and COUP
e relative expression of HA/COUP-TFI or COUP-TFI proteins in the
munofluorescence as described in Methods; the nuclei were
ed by a real-time PCR analysis from two independent MCF-7
sed as an internal control. The results were expressed as the relative
± SEM of at least three independent experiments. The asterisks indicate
e amount of intracellular HA/COUP-TFI, COUP-TFI, CXCL12, CXCR4,
MCF-7 clones and compared to total ERK. A representative western
munofluorescence cytochemistry assay was used to detect the relative
presented to visualize the nucleus of the cells.
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genes but did not affect CXCR7 expression (Figure 1B).
Indeed, a repression of 70% of the basal expression of
CXCL12 was observed in the COUP clones compared
to the control clones. In contrast, we observed a 6-fold
induction of the basal expression of the CXCR4 gene;
CXCR7 expression was not affected when we compared
COUP clones with the control clones. These results were
next confirmed at the protein level using western blotting
and immunofluorescence methods. The COUP clones dis-
played a striking reduction in CXCL12 protein expression
(Figure 1C and Figure 1D), whereas the CXCR4 protein
was remarkably up-regulated when compared to the
control clones (Figure 1C and Figure 1D). The CXCR7
protein did not change between the different clones
(Figure 1C and D). Altogether, our results suggest that
COUP-TFI overexpression selectively modulates the basal
expression of CXCL12/CXCR4 signaling.
Structural modifications at the CXCL12 and CXCR4
promoters
The level of chromatin compaction appears to be well
correlated with its activity, and numerous studies have
reported that active transcriptional regulatory sites are
present within open chromatin regions in which the nu-
cleosomes have been depleted .
These nucleosome-depleted genomic regions can be
enriched from chromatin preparations using the FAIRE
method [28]. Hence, we used FAIRE to monitor the ef-
fect of COUP-TFI on the chromatin structure of the
promoters of the CXCL12, CXCR4 and CXCR7 genes in
our MCF-7 clones. Interestingly, COUP-TFI overexpres-
sion led to an 80% decrease in the amount of DNA cor-
responding to the open CXCL12 promoter (Figure 2A). In
contrast, the CXCR4 promoter was significantly enriched
(2-fold) in the nucleosome-depleted DNA in the cellsFigure 2 COUP-TFI modulates the chromatin structure of the CXCL12
described in Methods. Real-time PCR was performed to monitor the enrich
(A), the CXCR4 (B) and the CXCR7 (C) genes relative to the input chromatin
samples and are representative of three separate experiments. The asterisk
COUP clones.overexpressing COUP-TFI compared to the MCF-7 con-
trol cells (Figure 2B). Concerning CXCR7, no significant
modifications were observed for the chromatin structure
of its promoter between the control and COUP clones
(Figure 2C). This result suggests that COUP-TFI select-
ively triggers a remodeling of the chromatin of both the
CXCL12 and CXCR4 promoters toward a more condensed
structure (CXCL12) or an open structure (CXCR4), which
are well correlated to the transcriptional activities ob-
served for these two genes.
COUP-TFI overexpression alters CXCL12/CXCR4 estrogenic
regulation
Our earlier studies have shown that COUP-TFI modulates
ERα transcriptional activity and is able to selectively mod-
ify the estrogenic regulation of estrogen-sensitive genes
[8,9,11,29]. Because the expression of CXCL12 and CXCR4
are regulated by estrogenic signals in breast cancer cells
[23], we investigated the impact of COUP-TFI on the es-
trogenic regulation of the CXCL12 and CXCR4 genes by
treating the MCF-7 clones with 10−8 M E2, 10−6 M ICI, or
both for 48 h.
As expected, treatment of the control MCF-7 cells with
E2 for 48 h resulted in the enhanced expression of CXCL12
(~11-fold induction, Figure 3A) and CXCR4 (~2-fold induc-
tion, Figure 3B) in comparison to the untreated and ICI-
treated cells. The up-regulation of CXCL12 expression by
E2 was also observed in the COUP cells treated with E2.
However, the relative level of CXCL12 expression was per-
sistently and significantly 30% lower in the COUP cells com-
pared with the control cells (Figure 3A). CXCR4 expression
was constitutively enhanced in the COUP clones, and nei-
ther E2 nor ICI, alone or in combination, had an effect on
this increased CXCR4 expression (Figure 3B). This result
suggests that the constitutive effect of COUP-TFI overex-
pression on CXCR4 mRNA is independent of ER signaling.and CXCR4 gene promoters. The FAIRE assay was performed as
ment of DNA corresponding to the proximal promoter of the CXCL12
from the control (Cont.) and COUP clones. The data are from triplicate
indicates significant differences (p < 0.05) between the control and
Figure 3 Estrogenic regulation of CXCL12 and CXCR4 in control and COUP clones. Control (Cont.) and COUP clones were treated with ethanol
(EtOH) as the vehicle or E2 10−8 M and ICI 10−6 M alone or both together for 48 h. The CXCL12 (A) and CXCR4 (B) relative mRNA levels were
monitored by a real-time PCR analysis, normalized to GAPDH mRNA as the internal control, and were expressed as the relative mRNA expression of
CXCL12 or CXCR4. Data are the mean ± SEM of at least three independent experiments. The asterisks indicate significant differences (p < 0.05) between
the untreated and treated control clones. The pound sign indicates significant differences (p < 0.05) between the untreated and treated COUP clones.
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and MAPK signaling pathways
The growth factor control of cell fate is a pivotal step in
cancer progression; indeed, the high expression of epi-
dermal growth factor receptor (EGFR) in cancers has
been associated with metastatic tumors and poor clinical
outcomes. Additionally, EGFR signaling was recently
linked to CXCR4 signaling [30]. Therefore, we evaluated
the effect of COUP-TFI on the expression of EGF and
EGFR (ErbB-1) in MCF-7 clones (Figure 4A) and found
that COUP-TFI overexpression increased both EGF and
EGFR expression by 1.8 to 2 times, respectively, in com-
parison to the MCF-7 control cells. Moreover, our earlier
studies have shown that COUP-TFI was able to interplay
with the MAPK pathway, enhancing ERK activity [8,9].
We confirmed this observation by analyzing ERK protein
phosphorylation after the EGF stimulation of COUP cells
in comparison to the control cells (Figure 4B). To further
investigate whether the up-regulation of EGF signaling by
COUP-TFI could be linked to the changes in CXCL12 and
CXCR4 gene expression, treatments with EGF and select-
ive inhibitors for EGFR (AG1478) and MEK (U0126) sig-
naling were performed. Interestingly, EGF treatment
significantly decreased CXCL12 expression in both the
control and COUP clones (Figure 4C), whereas the inhib-
ition of EGFR signaling by AG1478 and U0126 led to
a slight but significant elevation in CXCL12 expression
in both cells. The expression profile of CXCL12 was
lower under all conditions in the MCF-7 cells overex-
pressing COUP-TFI. Furthermore, EGF treatment in-
creased CXCR4 mRNA expression in the control cells
but had no effect on the increased CXCR4 expression in
the COUP cells (Figure 4D). Treatments with EGFR and
MEK inhibitors decreased CXCR4 expression, reaching a
lower level of expression than under the basal conditions.Indeed, the inhibition of EGFR and MAPK signaling abol-
ished the stimulation effect of COUP-TFI on CXCR4
expression.
COUP-TFI overexpression modifies cells response to
CXCL12 signal
The CXCL12/CXCR4 axis plays major roles in breast
cancer cell proliferation, migration, and invasion; thus,
we analyzed the CXCL12-mediated growth and motility
of MCF-7 cells overexpressing COUP-TFI (Figure 5).
First, we tested the control and COUP cells for a prolif-
erative response to CXCL12 treatment by exposing the
cells to CXCL12 (200 ng/mL) for 7 days and quantifying
the total cell number (Figure 5A). No significant differ-
ences were observed with regard to the basal growth of
the control and COUP cells; however, when treated with
CXCL12, both cells proliferated significantly more than
under the control condition. Furthermore, the COUP cells
displayed a significantly higher proliferative response to
the CXCL12 treatment than the control cells.
The cell migratory behavior was then assayed. We an-
alyzed the capacity of the control and COUP cells to mi-
grate through a PET membrane with an 8-μm filter pore
toward a low serum concentration medium, which rep-
resented the “basal” migration, or toward a CXCL12 gra-
dient, which corresponded to the “induced” migration
(Figure 5B). After a 24-h period, the relative number of
basal migrant cells was almost twice as high for the
COUP cells than the control cells. Moreover, when
CXCL12 (200 ng/mL) was added to the lower chamber,
the migration of the control and COUP cells increased
versus the basal condition. The relative induced migra-
tion of the COUP cells was 3 times higher than that of
the control cells. Interestingly, the specific CXCR4 in-
hibitor AMD3100 completely abolished the CXCL12-
Figure 4 The effect of COUP-TFI on the CXCL12/CXCR4 axis is mediated by EGF/EGFR activation. (A) The relative expression of EGF and
EGFR mRNA was monitored by a real-time PCR analysis using MCF-7 control (Cont.) and COUP clones. The results were normalized against GAPDH
as the internal control and are expressed as the mean EGF or EGFR mRNA/GAPDH mRNA ratio ± SEM of at least three independent experiments.
The asterisks indicate significant differences (p < 0.05) between the control and COUP clones. (B) ERK activation was examined in the MCF-7
control (Cont.) and COUP clones after a 5- or 10-min stimulation with EGF (10−9 M) or CXCL12 (200 ng/mL). Western blots were performed using
antibodies against phospho-ERK (P-ERK) and total ERK (ERK1/2); a representative western blot is presented. The importance of EGFR-specific
signaling and general ERK signaling on CXCL12 (C) and CXCR4 (D) regulation was assayed by treating the cells with EGF (10−9 M), AG1478
(25 μM), or U0126 (25 μM) for 48 h. The CXCL12 and CXCR4 relative mRNA levels were monitored by the real-time PCR analysis, normalized to
GAPDH mRNA as the internal control, and were expressed as the relative mRNA expression of CXCL12 or CXCR4. Data are the mean ± SEM of at
least three independent experiments. The asterisks indicate significant differences (p < 0.05) between the untreated and treated control clones.
The pound sign indicates significant differences (p < 0.05) between the untreated and treated COUP clones.
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http://www.biomedcentral.com/1471-2407/14/407induced migration observed in the control and COUP
cells. No significant difference in migration capability
between the two clones was detected.
Next, we tested the hypothesis that the reduction of
CXCL12 by the COUP cells is important for their migra-
tion toward a CXCL12 gradient. We therefore added hu-
man recombinant CXCL12 to both the upper chamber
and the lower chamber. Under these conditions, the
migratory behavior of the control and COUP cells was
dramatically altered, with both clones displaying an ap-
proximately similar migration potential (Figure 5C). Thus,
disruption of the CXCL12 gradient by ectopic CXCL12
added to the upper chamber prior to the migration test
hampered the migration of both the control and COUP
clones.CXCL12/CXCR4/CXCR7 and COUP-TFI mRNA expression in
breast tumors
The expression profiles of CXCR4, CXCR7, CXCL12,
and COUP-TFI in breast cancer cells from patients exhi-
biting different tumor grades (82 breast tumors and con-
trol non-tumor samples) were measured using real-time
PCR (Figure 6). As depicted in Figure 6A, the level of
CXCR4 mRNA was found to be significantly increased in
the tumors compared to the healthy samples (p < 0.0001).
A two-sided Pearson correlation was performed to seek
whether a correlation exists between CXCR4 expression
and the tumor grades. Indeed, we have found a strong
correlation between CXCR4 expression and tumor grade
(p-value = 0.000085, ρ = 0.4201 at the 95% confidence
interval [0.2235; 0.5839]). Conversely, the expression of
Figure 5 COUP-TFI overexpression influences cellular responses to CXCL12. (A) The relative growth of the control (Cont.) and COUP clones
was assayed with or without CXCL12 treatment for 7 days. The basal and CXCL12-induced cell growth were evaluated by MTT assays (n = 6) and
determined in three independent experiments. The results are expressed as the relative cell number obtained when the control cells were treated
with the vehicle control. Significant differences between the unstimulated control cells and the other conditions (p < 0.05) are indicated with an
asterisk. Significant differences between stimulated control cells and stimulated COUP clones (p < 0.05) are indicated with a pound sign. (B) The
migratory capacity of control (Cont.) and COUP clones was analyzed. The cells were maintained in phenol red-free DMEM/2.5% dsFBS for 48 h
and then seeded in phenol red-free DMEM/0.5% dsFBS in the upper chamber of a PET 8-μm pore insert. The cells were allowed to migrate for
24 h toward the phenol red-free DMEM/2.5% dsFBS medium complemented or not with CXCL12 (200 ng/mL) and AMD3100 (50 μM). (C) CXCL12
was also added to the culture medium in the upper chamber prior to migration. The results are expressed as the mean ± SEM of the relative
number of migratory cells compared to the basal migration of the control cells measured in three independent experiments. The asterisks
indicate significant differences (p < 0.05) from the basal migration of the control clones. The pound sign indicates significant differences
(p < 0.05) between two conditions linked by black lines.
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spectively) was significantly decreased in the tumors com-
pared to the healthy samples. As expected, COUP-TFI
(Figure 6D) was found to be significantly overexpressed in
the grade 1 tumors compared to normal tissues (p < 0.01)
though was rather similar in the grade 2 and 3 tumors
compared to that found in the normal samples. We have
also performed a two-sided Pearson correlation analysis to
determine if the relative expression of CXCR4, CXCR7
and CXCL12 in tumours is associated with the relative
expression of COUP-TFI. This analysis showed a signifi-
cant correlation for CXCR4/COUP-TFI (p-value = 0.029,
ρ = 0.2405 at the 95% confidence interval [0.0248; 0.4348]),
CXCR7/COUP-TFI (p-value = 0.0042, ρ = 0.3129 at the95% confidence interval [0.1029 ; 0.4962]) and CXCL12/
COUP-TFI (p-value = 0.030, ρ = 0.2387 at the 95% confi-
dence interval [0.0229; 0.4333]). Moreover, our in vitro ob-
servations correlate well with these results, indicating that
the expression of COUP-TFI and CXCR4 are enhanced,
with the expression of CXCL12 declining, during cell trans-
formation, resulting in the progression to a cancerous state.
Discussion
The contribution of COUP-TFI to cancer progression is
poorly understood. Nevertheless, this orphan nuclear re-
ceptor is known to participate in many biological processes
connected to normal or pathological cell proliferation, sur-
vival, or migration (for a review, see [11]). Previous studies
Figure 6 Box plots of CXCR4, CXCR7, CXCL12, and COUP-TFI mRNA expression in breast cancer and normal tissue. CXCR4 (A), CXCR7
(B), CXCL12 (C), and COUP-TFI (D) mRNA expression was measured by real-time PCR in 23 normal breast tissue samples (NT), in 20 SBR grades 1
and 2, and in 19 SBR grades 3. The expression level was normalized by 18S RNA expression and analyzed with IQ5 software (Bio-Rad). The data
are presented as whisker plots in which the horizontal bar represents the median, the grey boxes are the 25th and 75th percentiles, the vertical
bar is the standard deviation, and the plus signs are the extreme points. All the Mann-Whitney tests were performed with Minitab 16 software,
and the p value is indicated on the different graphs (ns denotes non-significant).
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signaling, contributing to phenotypical changes in breast
cancer cells [9,31,32]. Moreover, our previous study sug-
gested that the overexpression of COUP-TFI in breast
tumor cells may contribute to the loss of the epithelial
phenotype and acquisition of mesenchymal characteristics
[9]. In the present study, we identified CXCL12/CXCR4
signaling as an endogenous target of COUP-TFI, which
could explain some of these phenotypical deviations. We
demonstrated that COUP-TFI overexpression selectively
and differentially alters the expression of the CXCL12 and
CXCR4 genes: the basal level of CXCL12 was reduced,
whereas CXCR4 basal expression was up-regulated. It was
also noted that COUP-TFI disturbs the estrogenic regula-
tion of CXCL12 and CXCR4 in MCF-7 cells, supporting
the idea that COUP-TFI leads to a loss of E2 dependency
in breast cancer cells. Interestingly, our data show that
COUP-TFI impacts the chromatin condensation state of
the proximal promoters of the CXCL12 and CXCR4 genes.
These modifications of the chromatin structure are known
to correlate with the transcriptional potential of regulatory
elements and could also suggest epigenetic modifications
induced by COUP-TFI. However, the precise molecular
mechanisms of COUP-TFI action on the basal and E2-
dependent regulation of CXCL12/CXCR4 remain to be
determined.Cancer progression is frequently associated with growth
factor-induced control of cell growth and migration [33].
Notably, cross-talk between the EGFR family and E2 sig-
naling is often associated with the loss of hormonal con-
trol of cancer cell growth and the acquisition of metastatic
potential [34]. CXCR4 induction is one of the identified
mechanisms for the growth factor control in cancer cells,
which supports the migration of cancer cells [30]. COUP-
TFI has been shown to interact with the MAPK pathway,
leading to the activation of ERK activity ([8] and herein).
Here, we established that COUP-TFI overexpression leads
to an increase in EGF and EGFR relative expression that
could, in part, explain the effect of COUP-TFI in the acti-
vation of ERK signaling activity. Our results support that
the induction of MAPK activity, presumably via EGF
signaling, is responsible for the constitutive induction
effected by COUP-TFI on CXCR4 expression. More-
over, our results show for the first time that CXCL12
expression is negatively regulated by EGF signaling in
breast cancer cells. We also observed similar results
when the cells were treated with different serum con-
centrations (data not shown). Interestingly, these data are
in good agreement with several studies related to stem cell
homing/mobilization in bone marrow that have reported
that many growth factors can down-regulate the local
secretion of CXCL12, thereby promoting stem cell
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http://www.biomedcentral.com/1471-2407/14/407mobilization toward the peripheral blood [35-37]. Taken
together, our results support the idea that COUP-TFI can
differentially impact CXCL12 and CXCR4 basal expres-
sion by activating the ERK pathway. The constitutive acti-
vation of a transcription factor—proposed not to be ERα,
given our observation that ICI treatment did not impact
CXCR4 expression in COUP clones—by the MAPK path-
way could explain the induction of CXCR4 expression. It
was previously observed that hypoxia-inducible factor 1
alpha (HIF1-α) is induced by EGFR constitutive signaling,
leading to CXCR4 up-regulation [30].
The chemokine network and CXCL12/CXCR4 signal-
ing in particular, as well as EGFR signaling are involved
in many aspects of cancer biology, including growth and
metastasis [7,34,38]. Indeed, there are many evidences of
the essential role of CXCR4 in the enhanced invasion of
several types of cancer [39-41]. Furthermore, the down-
regulation of CXCL12 expression by promoter hyperme-
thylation has been associated with increased metastatic
potential in mammary carcinoma cells [22] by the loss of
autocrine and paracrine CXCL12 retention at the pri-
mary tumor site. Our results demonstrate a higher prolif-
erative response to CXCL12 treatment by COUP clones
compared to control clones, which could be due to the
higher activation of ERK signaling observed after CXCL12
treatment. We also found that the COUP clones exhibited
a better migration behavior than the control clones when
migrating toward a serum-complemented medium or in
response to a CXCL12 chemotactic gradient. Our results
suggest that this higher migration behavior is due to the
enhanced CXCR4 expression. In addition, we observed
that ectopic CXCL12 added to the upper chamber prior to
the migration test hampered the migration of both the
control and COUP clones. This finding is in good agree-
ment with a study from Zabel et al., who suggested that
the reduction in CXCL12-triggered migration by the
additional CXCL12 within the cells could possibly be
explained by the desensitization of CXCR4 or disruption
of the chemokine gradient [42]. Moreover, the down-
regulation of CXCL12 was previously reported to be ne-
cessary to allow the emergence of metastatic cells in vivo
[20,21]. Taken together, our results suggest that the down-
regulation of CXCL12 induced by COUP-TFI overexpres-
sion could be associated, together with the elevation in
CXCR4 expression, with increased migration behavior.
In other words, we propose that the opposite action
of COUP-TFI on CXCL12 and CXCR4 expression en-
hances the migration capacity of cancer cells through
an increase in sensitivity to exogenous CXCL12 and by
limiting the autocrine retention effect of CXCL12. More-
over, enhanced EGFR signaling activity was reported to
contribute to cancer progression from various origins
through the elevation of cancer cell survival, proliferation,
and migration [38]. Our results support that, by repressingCXCL12 expression and inducing CXCR4 expression,
the growth factor regulation of CXCL12 signaling could
trigger these effects, as was observed during stem
cell mobilization from the bone marrow to periph-
eral blood [43].
Our previous immunohistochemistry data indicated
that COUP-TFI is overexpressed in cancer compared to
normal breast tissues [9]. We also showed that COUP-
TFI expression increased in dedifferentitiated ER-negative
breast cancer cell lines compared to differentiated ER-
positive cell lines. This was correlated to protein markers
of dedifferentiated phenotype, for instance E-cadherin si-
lencing and vimentin expression [9]. A limitation of our
study is that it was only performed in MCF-7 cell line.
However, it is of interest to note that COUP-TFI represses
in vitro the expression of type VII collagen in different hu-
man cell lines [44]. Moreover, cell contact stability was re-
ported to be affected by COUP-TFI overexpression in
fibroblast cells, most likely because of alteration of cell at-
tachment proteins expression [45]. COUP-TFII has also
been reported to be overexpressed in breast cancer epithe-
lia [12]. COUP-TFII over expression was furthermore as-
sociated to poor clinical outcome and to invasive behavior
of metastatic cells in lymph nodes [12]. However, in this
study, our quantitative RT-PCRs revealed a significant
augmentation of COUP-TFI mRNA expression only in
grade 1 tumors, whereas grade 2 and 3 tumors exhibited
expression of COUP-TFI mRNA that was similar to that
observed in the normal tissues. Although, further investi-
gation, particularly by immunohistochemistry, is necessary
to reveal COUP-TFI staining in low and high grade tumor
biopsies, the discrepancy between transcript and protein
levels, may argue for the consequence of additional con-
trol mechanisms besides transcription. This may be attrib-
uted to differences in the mRNA and protein turn over or
could originate from different translational mechanisms
that may selectively stabilize COUP-TFI protein. Indeed,
the expression levels of a protein depend not only on tran-
scription rates of the gene, but also on additional control
mechanisms, such as nuclear export, mRNA localization
and stability, translational regulation and protein degrad-
ation [46]. Deregulation of certain of these mechanisms in
cancer cells may explain this discrepancy; however, more
investigations will be needed to establish that. Interest-
ingly, our in vitro results showed that COUP-TFI overex-
pression does abolish E2 control of CXCR4 expression
and partially reduces CXCL12 regulation. The expression
profiles of CXCL12, CXCR4 and CXCR7 in breast cancer
biopsies are almost identical to that obtained when we
overexpressed COUP-TFI in MCF-7 cancer cells, suggest-
ing that our in-vitro results might have a clinical rele-
vance. It should be investigated whether increasing the
expression of COUP-TFI protein during cancer progres-
sion could in fact participate in the development of
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capacity of tumor cells. Recent studies have reported that
the COUP-TFII expression level is increased in sev-
eral different cancer cells, such as breast, prostate, and
ovary cancers [12-14]. These studies have also shown that
the overexpression of COUP-TFII is associated with a
significantly shorter disease-free survival. Indeed, the
overexpression of COUP-TFII in prostate cells promotes
tumorigenesis and induces an aggressive metastasis char-
acteristic in tumors by inhibiting the TGF-β-induced
growth barrier [13].
Conclusion
In summary, we identified the CXCL12 signaling axis as
an endogenous target of the orphan nuclear receptor
COUP-TFI. The effect of COUP-TFI is mediated by the
induction of MAPK signaling and leads to enhanced
growth and migration capacity in cancer cells in response
to CXCL12. Although the clinical importance of these ob-
servations should be investigated further, our results pre-
dict that the disruption of COUP-TFI in breast cancer
may result in the reduction of the metastatic potential of
the cells.
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